Image-guided adaptive brachytherapy (Igabt) for primary vaginal cancer: Results of the international multicenter retroembrave cohort study

Henrike Westerveld; Maximilian P. Schmid; Remi A. Nout; Cyrus Chargari; Bradley R. Pieters; Carien L. Creutzberg; Alina Sturdza; Jacob C. Lindegaard; Zdenko van Kesteren; Renaud Mazeron; Nicole Nesvacil; Lars U. Fokdal

doi:10.3390/cancers13061459

Image-guided adaptive brachytherapy (Igabt) for primary vaginal cancer: Results of the international multicenter retroembrave cohort study

Henrike Westerveld^*, Maximilian P. Schmid, Remi A. Nout, Cyrus Chargari, Bradley R. Pieters, Carien L. Creutzberg, Alina Sturdza, Jacob C. Lindegaard, Zdenko van Kesteren, Renaud Mazeron, Nicole Nesvacil, Lars U. Fokdal

^*Corresponding author for this work

Radiotherapy

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

23 Downloads (Pure)

Abstract

Purpose: This study assessed outcomes following the nowadays standing treatment for primary vaginal cancer with radio(chemo)therapy and image-guided adaptive brachytherapy (IGABT) in a multicenter patient cohort. Methods: Patients treated with computer tomography (CT)–MRI-assisted-based IGABT were included. Retrospective data collection included patient, tumor and treatment characteristics. Late morbidity was assessed by using the CTCAE 3.0 scale. Results: Five European centers included 148 consecutive patients, with a median age of 63 years. At a median follow-up of 29 months (IQR 25–57), two-and five-year local control were 86% and 83%; disease-free survival (DFS) was 73% and 66%, and overall survival (OS) was 79% and 68%, respectively. Crude incidences of ≥ grade-three urogenital, gastro-intestinal and vaginal morbidity was 8%, 3% and 8%, respectively. Lymph node metastasis was an independent prognostic factor for disease-free survival (DFS). Univariate analysis showed improved local control in patients with T2–T4 tumors if >80 Gy EQD2_α/β10 was delivered to the clinical target volume (CTV) at the time of brachytherapy. Conclusions: In this large retrospective multicenter study, IGABT for primary vaginal cancer resulted in a high local control with acceptable morbidity. These results compared favorably with two-dimensional (2D) radiograph-based brachytherapy and illustrate that IGABT plays an important role in the treatment of vaginal cancer.

Original language	English
Article number	1459
Journal	Cancers
Volume	13
Issue number	6
DOIs	https://doi.org/10.3390/cancers13061459
Publication status	Published - 23 Mar 2021

Bibliographical note

Funding Information:
Conflicts of Interest: Maximilian Schmid, Alina Sturdza, and Nicole Nesvacil receive personal grants from Elekta outside the submitted work. Remi Nout receives grants from Elekta, Varian Medical Systems and Accuray outside the submitted work. Cyrus Chargari receives personal grants and nonfinancial support from Takeda and MSD, service as an investigator for clinical trials sponsored by TherAgulX and Roche, and personal grants from Elekta outside the submitted work. Jacob Lindegard receives a personal grant from Varian Medical Systems outside the submitted work. The other authors declare no conflict of interest.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13061459Licence: CC BY

Image-Guided Adaptive Brachytherapy (IGABT) for Primary Vaginal Cancer Results of the International Multicenter RetroEMBRAVE Cohort StudyFinal published version, 2.27 MBLicence: CC BY

Cite this

Westerveld, H., Schmid, M. P., Nout, R. A., Chargari, C., Pieters, B. R., Creutzberg, C. L., Sturdza, A., Lindegaard, J. C., van Kesteren, Z., Mazeron, R., Nesvacil, N., & Fokdal, L. U. (2021). Image-guided adaptive brachytherapy (Igabt) for primary vaginal cancer: Results of the international multicenter retroembrave cohort study. Cancers, 13(6), Article 1459. https://doi.org/10.3390/cancers13061459

@article{977adf737f344be885ba75d2faff34cf,

title = "Image-guided adaptive brachytherapy (Igabt) for primary vaginal cancer: Results of the international multicenter retroembrave cohort study",

abstract = "Purpose: This study assessed outcomes following the nowadays standing treatment for primary vaginal cancer with radio(chemo)therapy and image-guided adaptive brachytherapy (IGABT) in a multicenter patient cohort. Methods: Patients treated with computer tomography (CT)–MRI-assisted-based IGABT were included. Retrospective data collection included patient, tumor and treatment characteristics. Late morbidity was assessed by using the CTCAE 3.0 scale. Results: Five European centers included 148 consecutive patients, with a median age of 63 years. At a median follow-up of 29 months (IQR 25–57), two-and five-year local control were 86% and 83%; disease-free survival (DFS) was 73% and 66%, and overall survival (OS) was 79% and 68%, respectively. Crude incidences of ≥ grade-three urogenital, gastro-intestinal and vaginal morbidity was 8%, 3% and 8%, respectively. Lymph node metastasis was an independent prognostic factor for disease-free survival (DFS). Univariate analysis showed improved local control in patients with T2–T4 tumors if >80 Gy EQD2α/β10 was delivered to the clinical target volume (CTV) at the time of brachytherapy. Conclusions: In this large retrospective multicenter study, IGABT for primary vaginal cancer resulted in a high local control with acceptable morbidity. These results compared favorably with two-dimensional (2D) radiograph-based brachytherapy and illustrate that IGABT plays an important role in the treatment of vaginal cancer.",

author = "Henrike Westerveld and Schmid, {Maximilian P.} and Nout, {Remi A.} and Cyrus Chargari and Pieters, {Bradley R.} and Creutzberg, {Carien L.} and Alina Sturdza and Lindegaard, {Jacob C.} and {van Kesteren}, Zdenko and Renaud Mazeron and Nicole Nesvacil and Fokdal, {Lars U.}",

note = "Funding Information: Conflicts of Interest: Maximilian Schmid, Alina Sturdza, and Nicole Nesvacil receive personal grants from Elekta outside the submitted work. Remi Nout receives grants from Elekta, Varian Medical Systems and Accuray outside the submitted work. Cyrus Chargari receives personal grants and nonfinancial support from Takeda and MSD, service as an investigator for clinical trials sponsored by TherAgulX and Roche, and personal grants from Elekta outside the submitted work. Jacob Lindegard receives a personal grant from Varian Medical Systems outside the submitted work. The other authors declare no conflict of interest. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = mar,

day = "23",

doi = "10.3390/cancers13061459",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "6",

}

Westerveld, H, Schmid, MP, Nout, RA, Chargari, C, Pieters, BR, Creutzberg, CL, Sturdza, A, Lindegaard, JC, van Kesteren, Z, Mazeron, R, Nesvacil, N & Fokdal, LU 2021, 'Image-guided adaptive brachytherapy (Igabt) for primary vaginal cancer: Results of the international multicenter retroembrave cohort study', Cancers, vol. 13, no. 6, 1459. https://doi.org/10.3390/cancers13061459

TY - JOUR

T1 - Image-guided adaptive brachytherapy (Igabt) for primary vaginal cancer

T2 - Results of the international multicenter retroembrave cohort study

AU - Westerveld, Henrike

AU - Schmid, Maximilian P.

AU - Nout, Remi A.

AU - Chargari, Cyrus

AU - Pieters, Bradley R.

AU - Creutzberg, Carien L.

AU - Sturdza, Alina

AU - Lindegaard, Jacob C.

AU - van Kesteren, Zdenko

AU - Mazeron, Renaud

AU - Nesvacil, Nicole

AU - Fokdal, Lars U.

N1 - Funding Information: Conflicts of Interest: Maximilian Schmid, Alina Sturdza, and Nicole Nesvacil receive personal grants from Elekta outside the submitted work. Remi Nout receives grants from Elekta, Varian Medical Systems and Accuray outside the submitted work. Cyrus Chargari receives personal grants and nonfinancial support from Takeda and MSD, service as an investigator for clinical trials sponsored by TherAgulX and Roche, and personal grants from Elekta outside the submitted work. Jacob Lindegard receives a personal grant from Varian Medical Systems outside the submitted work. The other authors declare no conflict of interest. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/3/23

Y1 - 2021/3/23

N2 - Purpose: This study assessed outcomes following the nowadays standing treatment for primary vaginal cancer with radio(chemo)therapy and image-guided adaptive brachytherapy (IGABT) in a multicenter patient cohort. Methods: Patients treated with computer tomography (CT)–MRI-assisted-based IGABT were included. Retrospective data collection included patient, tumor and treatment characteristics. Late morbidity was assessed by using the CTCAE 3.0 scale. Results: Five European centers included 148 consecutive patients, with a median age of 63 years. At a median follow-up of 29 months (IQR 25–57), two-and five-year local control were 86% and 83%; disease-free survival (DFS) was 73% and 66%, and overall survival (OS) was 79% and 68%, respectively. Crude incidences of ≥ grade-three urogenital, gastro-intestinal and vaginal morbidity was 8%, 3% and 8%, respectively. Lymph node metastasis was an independent prognostic factor for disease-free survival (DFS). Univariate analysis showed improved local control in patients with T2–T4 tumors if >80 Gy EQD2α/β10 was delivered to the clinical target volume (CTV) at the time of brachytherapy. Conclusions: In this large retrospective multicenter study, IGABT for primary vaginal cancer resulted in a high local control with acceptable morbidity. These results compared favorably with two-dimensional (2D) radiograph-based brachytherapy and illustrate that IGABT plays an important role in the treatment of vaginal cancer.

AB - Purpose: This study assessed outcomes following the nowadays standing treatment for primary vaginal cancer with radio(chemo)therapy and image-guided adaptive brachytherapy (IGABT) in a multicenter patient cohort. Methods: Patients treated with computer tomography (CT)–MRI-assisted-based IGABT were included. Retrospective data collection included patient, tumor and treatment characteristics. Late morbidity was assessed by using the CTCAE 3.0 scale. Results: Five European centers included 148 consecutive patients, with a median age of 63 years. At a median follow-up of 29 months (IQR 25–57), two-and five-year local control were 86% and 83%; disease-free survival (DFS) was 73% and 66%, and overall survival (OS) was 79% and 68%, respectively. Crude incidences of ≥ grade-three urogenital, gastro-intestinal and vaginal morbidity was 8%, 3% and 8%, respectively. Lymph node metastasis was an independent prognostic factor for disease-free survival (DFS). Univariate analysis showed improved local control in patients with T2–T4 tumors if >80 Gy EQD2α/β10 was delivered to the clinical target volume (CTV) at the time of brachytherapy. Conclusions: In this large retrospective multicenter study, IGABT for primary vaginal cancer resulted in a high local control with acceptable morbidity. These results compared favorably with two-dimensional (2D) radiograph-based brachytherapy and illustrate that IGABT plays an important role in the treatment of vaginal cancer.

UR - http://www.scopus.com/inward/record.url?scp=85102812842&partnerID=8YFLogxK

U2 - 10.3390/cancers13061459

DO - 10.3390/cancers13061459

M3 - Article

C2 - 33806733

AN - SCOPUS:85102812842

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 6

M1 - 1459

ER -

Image-guided adaptive brachytherapy (Igabt) for primary vaginal cancer: Results of the international multicenter retroembrave cohort study

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this